Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is -14.35% lower on its value in year-to-date trading and has touched a low of $6.07 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHAT stock was last observed hovering at around $7.99 in the last trading session, with the day’s loss setting it -0.17%.
Currently trading at $7.82, the stock is -9.86% and -36.95% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing -2.13% at the moment leaves the stock -35.60% off its SMA200. PHAT registered -10.53% loss for a year compared to 6-month loss of -29.42%. The firm has a 50-day simple moving average (SMA 50) of $12.5612 and a 200-day simple moving average (SMA200) of $12.151825.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -16.54% gain in the last 1 month and extending the period to 3 months gives it a -57.57%, and is -2.07% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.58% over the week and 7.76% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $534.72M and $26.27M in sales. Profit margin for the company is -1292.14%. Distance from 52-week low is 28.94% and -60.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-109.14%).
The EPS is expected to shrink by -37.62% this year
200.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 119.82% of the company’s shares. The shares outstanding are 68.32M, and float is at 34.87M with Short Float at 40.31%. Institutions hold 110.56% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.3189 of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.788 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9906 and valued at over $35.84 million, while INVESCO LTD. holds 5.3853 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider purchase by KARBE FRANK, the company’s Director. SEC filings show that KARBE FRANK bought 12,500 shares of the company’s common stock on Dec 13 ’24 at a price of $7.93 per share for a total of $99084.0. Following the purchase, the insider now owns 57000.0 shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 13 ’24 that Parikh Asit (Director) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Dec 13 ’24 and was made at $8.12 per share for $81248.0. Following the transaction, the insider now directly holds 75500.0 shares of the PHAT stock.
Still, SEC filings show that on Jul 15 ’24, Nabulsi Azmi (Chief Operating Officer) disposed off 10,901 shares at an average price of $11.72 for $0.13 million. The insider now directly holds 240,421 shares of Phathom Pharmaceuticals Inc (PHAT).
